Rocket Pharmaceuticals, Inc. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2021-09-30 was $5.15M.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2021-06-30 was $35.54M.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2018-12-31 was $0.00.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2018-09-30 was $0.00.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2021 was $40.69M, a 433.41% increase from fiscal 2020.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2020 was $7.63M.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2018 was $0.00.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2021-12-31 | $40.69M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $5.15M 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $35.54M 10-Q · filed 2022-11-04 | |
| 2020-12-31 | $7.63M 10-K · filed 2023-02-28 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | |
| 2018-03-31 | $0.00 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |